Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

Inclusion Criteria: * Males and females who are 20 or over * Patients who satisfy the classification criteria of Rheumatoid Arthritis according to American Colleague of Rheumatology (ACR 1987) * Patients who are applicable to functional status I - III of American Colleague of Rheumatology Exclusion Criteria: * Patients who have autoimmune diseases other than rheumatoid arthritis or have significant secondary systematic disease caused by rheumatoid arthritis * Patients who are currently participating in other clinical studies or receiving treatment for drugs not sold in the market or for experiment * Patients who have significant other diseases that may affect the clinical trial when judged by the clinical trial Investigator * In the opinion of the investigator, may put the patient at risk because of participation on the study or may influence the patients' ability to participate in the study